Overview

Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation and Atrial Flutter Who Underwent Catheter Ablation

Status:
Recruiting

Trial end date:
2024-10-30

Target enrollment:

Participant gender:

Summary

It is planned to evaluate the efficacy and safety of the class III antiarrhythmic drug refralon as a drug for pharmacological cardioversion in patients with recurrent atrial fibrillation (AF) and atrial flutter (AFL) after catheter ablation.

Phase:

N/A

Details

Lead Sponsor:

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation